Introduction
============

The one-carbon (1-C) transfer pathway refers to biologic reactions that depend on 1-C transfers mediated by folate coenzymes: these transfers play essential roles in many major cellular processes including nucleic acid biosynthesis and methyl group generation (Ulrich et al., [@B37]). Consequently, perturbations in this pathway caused by folate or 1-C donor nutrient deficiency can compromise DNA synthesis and methylation and can lead to tumorigenesis (Choi and Mason, [@B4]). Polymorphisms in genes involved in the 1-C transfer pathway may mimic folate or 1-C donor deficiency and influence the risk of cancers. However, risk may be modified by dietary factors such as folate and other 1-C donor nutrients (Ma et al., [@B22], [@B21]; Maruti et al., [@B23]; Levine et al., [@B19]).

We previously examined the association between single nucleotide polymorphisms (SNPs) in several genes in the 1-C transfer pathway and ovarian carcinoma risk, but found little evidence in secondary analyses for interactions with regular multivitamin supplement use as a source of folate and other B-vitamins (Kelemen et al., [@B14]). In that study, the smallest false positive report probabilities (FPRP) for interaction analyses were between 0.54 and 0.66 for associations between three SNPs in *DNMT3A* and risk of ovarian carcinoma among multivitamin supplement users (Kelemen et al., [@B14]).

In the present study, we elucidated the potential contribution of variants in three genes for which we hypothesized, *a priori*, would have interactive effects with multivitamin supplement use as a source of folate and other 1-C donor nutrients. Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) is a single bifunctional protein that catalyzes the penultimate and final steps of the *de novo* purine biosynthesis via a 1-C transfer from reduced folate (Wolan et al., [@B39]). The *ATIC* gene is highly conserved across several species from *Escherichia* *coli* to humans (Cheong et al., [@B3]). Serine hydroxymethyltransferase 2 (SHMT2) is the mitochondrial isoenzyme of cytoplasmic SHMT1. Both enzymes catalyze the reversible transfer of a single carbon from serine to tetrahydrofolate to form glycine and 5,10 methylene-tetrahydrofolate, which is required for *de novo* pyrimidine synthesis (Tibbetts and Appling, [@B36]). Polymorphisms in *SHMT1* have been reported to alter the risk of ovarian carcinoma (Kelemen et al., [@B14]), squamous cell carcinoma of the head and neck (Zhang et al., [@B43]), and lung carcinoma (Wang et al., [@B38]). Solute carrier protein 46A1 (SLC46A1) plays a critical role in the absorption of folate from diet by functioning as a proton-coupled folate transporter and as a mediator of folate receptor endocytosis (Qiu et al., [@B27]; Zhao et al., [@B45]). Nucleotide substitutions in *SLC46A1* that result in point mutations or a splice variant in the corresponding protein have recently been described in patients exhibiting hereditary folate malabsorption (Zhao et al., [@B44]).

We present here our findings for the associations between 15 common SNPs in *ATIC*, *SHMT2*, and *SLC46A1* and ovarian carcinoma risk, stratified by regular multivitamin supplement use as an estimate of B-vitamin intake, using data from two case--control studies including 968 cases and 1,265 controls.

Materials and Methods
=====================

Study population
----------------

The study population consisted of a combination of two individual studies of epithelial ovarian cancer from Mayo Clinic and Duke University. Details of the study protocols have been published previously (Sellers et al., [@B32]). Briefly, participants included Caucasians and African-Americans enrolled from June 1999 onward. Mayo Clinic cases were 20 years of age or older and resident in a six-state region (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, and South Dakota) that defined the primary catchment area. Controls were women seeking general medical care at Mayo Clinic. Duke University cases were between 20 and 74 years of age and identified from a 48-county region in North Carolina. Controls were identified from the same region using population-based list-assisted random digit dialing. In both studies, cases were newly diagnosed, histologically confirmed, of either borderline or invasive behavior, and enrolled within 1 year of diagnosis. Controls had at least one intact ovary, no history of ovarian cancer and were frequency-matched to cases on age (5-year age categories), race, and state of residence. The response among cases and controls, respectively, was high at Mayo Clinic (83 and 74%) and Duke University (75 and 64%). All participants provided written informed consent and procedures followed were in accordance with the Institutional Review Board of Mayo Clinic and the Institutional Review Board of Duke University Medical Center.

Assessment of regular multivitamin supplement use and other risk factors
------------------------------------------------------------------------

Multivitamin supplement use and information on established risk factors such as reproductive history, family history of cancer, medical history, and lifestyle habits were obtained from all subjects through in-person interviews using study-specific questionnaires. Variables were harmonized across studies for this analysis. The Mayo Clinic study began collecting information on multivitamin intake 3 years after the start of the study, while the Duke University study elicited this information from the start of the study. At Duke University, participants indicated their regularity of multivitamin use (none, \<1 pill per week, 1--2 per week, 3--4 per week, 5--6 per week, or daily) during the previous 5 years. We defined users as those who consumed at least three pills per week for at least 48 months during the past 5 years (e.g., allowing 80% adherence). At Mayo Clinic, participants responded yes or no to whether they consumed multivitamins at least four times per week during the previous year for controls and 1 year before diagnosis for cases; they also estimated their total number of years' duration of use. To create a "multivitamin user" definition that compared to the Duke University subjects, we defined Mayo Clinic users as women consuming at least four pills per week for at least 48 months' duration of lifetime use.

Genetic analysis
----------------

DNA was obtained from peripheral blood samples using salt extraction protocols (Sellers et al., [@B32]; Cunningham et al., [@B5]). In addition, whole genome amplification (WGA) using the REPLI-G WGA protocol (Qiagen Inc., Valencia, CA, USA) was used to enrich DNA samples from Duke University due to limited quantities. Excellent (\>99%) concordance between genomic and WGA DNA genotype calls for these samples has been reported previously (Cunningham et al., [@B5]).

TagSNPs were chosen using SNP information from unrelated Caucasian samples within HapMap Consortium's release 22 (The International HapMap Consortium, [@B35]) as previously described (Kelemen et al., [@B14]), and also for their predicted likelihood of successful genotyping using the Illumina Golden Gate Assay™. We selected nine tagSNPs in *ATIC* (rs3772078, rs2372536, rs1880586, rs1983462, rs16853826, rs7586969, rs16853834, rs1404772, and rs7604984) from among 45 individual SNPs, two tagSNPs in *SHMT2* (rs7301155 and rs2229716) from among two individual SNPs and four tagSNPs in *SLC46A1* (rs9894260, rs739439, rs2239908, and rs17719944) from among 10 individual SNPs using criteria of minor allele frequency (MAF) ≥ 0.05 and pairwise linkage disequilibrium (LD) of *r*^2^ \< 0.8. The SNPs were located within, and 5 kb upstream and downstream of, each gene region.

The 15 tagSNPs were genotyped using a phased study design. In the first phase (Phase 1), we genotyped the SNPs as part of a larger investigation of 1,152 SNPs in a variety of pathways using the Illumina GoldenGate™ assay and Illumina BeadStudio software (Oliphant et al., [@B26]; Fan et al., [@B7]; Steemers and Gunderson, [@B34]). Genotyping was attempted on 897 genomic DNA samples from Mayo Clinic and 1,279 WGA samples from Duke University (total = 2,176 including 129 duplicate samples) for subjects recruited through March 2006 as well as 65 laboratory controls. Of these samples, we excluded 44 (one Mayo Clinic sample and 43 Duke University samples) with call rates \< 90% and Illumina quality control (GenCall) scores \< 0.25, and 22 samples where the cancer was not of epithelial origin or the samples were mislabeled, resulting in 1,981 unique samples that were successfully genotyped. The sample call rate was 99.74% and the concordance for duplicate samples was 99.99%. All 15 tagSNPs in *ATIC*, *SHMT2*, and *SLC46A1* were genotyped successfully, except *SHMT2* rs7301155 that failed in Duke University samples. In Phase 2, we genotyped or imputed the 15 tagSNPs as part of a genome-wide association study (GWAS) of ovarian carcinoma using the Illumina 610 K chip on 186 genomic DNA samples from Mayo Clinic and 477 WGA samples from Duke University for subjects recruited after March 2006. Genotyping call rates for these SNPs were ≥ 99%. Imputation was performed using the MACH software (Li et al., [@B20]) and the phase II HapMap (release 22) referent genotypes for Caucasian samples for eight SNPs \[*ATIC* (rs2372536, rs1880586, rs1983462, rs16853826, and rs7586969), *SHMT2* (rs7301155 and rs2229716), and *SLC46A1* (rs9894260)\]. Because *SHMT2* rs7301155 failed in Duke University samples from Phase 1, we included the imputed genotypes for this SNP from both Phase 1 and Phase 2 Duke University samples represented on the GWAS. Squared correlations between imputed and true genotypes were between 0.93 and 0.99, except *r*^2^ = 0.43 for *SHMT2* rs2229716, which was likely due to its rare frequency (Table [A1](#TA1){ref-type="table"} in Appendix).

Statistical analysis
--------------------

Analyses were restricted to subjects who were self-reported Caucasian controls or cases with invasive epithelial ovarian carcinoma, resulting in a final sample size of 1,575 participants in Phase 1 from Mayo Clinic (312 cases and 439 controls) and Duke University (343 cases and 481 controls) and 658 participants in Phase 2 from Mayo Clinic (89 cases and 96 controls) and Duke University (224 cases and 249 controls). Genotypes of participants were used to estimate allele frequencies and chi squared tests were used to examine deviations of genotype frequencies from those expected under Hardy--Weinberg equilibrium (HWE) in control subjects. Pairwise LD was examined across all SNPs with the *r*^2^ statistic using Haploview (Barrett et al., [@B2]). Data from Mayo Clinic and Duke University were combined following confirmation of no statistical heterogeneity in SNP associations between study sites.

Our primary hypothesis was that SNP associations would be modified by regular multivitamin supplement use as a source of folate or other nutrients involved 1-C transfer. We evaluated this first in Phase 1 samples. Interactions were evaluated with the Wald test in models that included a one degree-of-freedom product term for regular multivitamin supplement use (yes/no) and the ordinal coding for genotype, in addition to the covariates age (\<40, 40--49, 50--59, 60--69, and 70+ years), region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina), SNP, regular multivitamin supplement use, body mass index, age at menarche, oral contraceptive use, postmenopausal status, postmenopausal hormone use, parity/age at first birth, smoking, and education (see Table [2](#T2){ref-type="table"} for categories). To determine the degree of falsely positive findings due to the number of interaction tests that were performed, we calculated *q*-values to estimate false discovery rates (FDR; Hochberg and Benjamini, [@B13]). Associations between SNPs and ovarian carcinoma were stratified by regular multivitamin supplement use and estimated as odds ratios (OR) with 95% confidence intervals (CI) using multivariable-adjusted unconditional logistic regression under ordinal genetic models. For SNPs where the tests for interaction had higher FDR *q*-values (e.g., \>0.23 in our data), suggesting a higher likelihood of falsely positive tests, we estimated associations between the genetic main effects and ovarian carcinoma under both co-dominant and ordinal genetic models. Models evaluating the main effects of SNPs were adjusted for age and region of residence. Adjustment for additional covariates did not change the ORs (data not shown).

###### 

**Characteristics of 2,233 Caucasian subjects (Phases 1 and 2), Mayo Clinic, and Duke University**.

                                                                          Mayo Clinic   Duke University                 
  ----------------------------------------------------------------------- ------------- ----------------- ------------- -------------
  Age, year \[mean (SD)\]                                                 61.0 (12.5)   60.7 (13.2)       57.3 (10.3)   55.3 (12.0)
  **BODY MASS INDEX, kg/m^2^**                                                                                          
  \<23 \[*n* (%)\]                                                        80 (20.5)     127 (24.8)        152 (27.6)    203 (28.4)
  23--26 \[*n* (%)\]                                                      100 (25.6)    150 (29.3)        131 (23.8)    173 (24.2)
  26--29 \[*n* (%)\]                                                      75 (19.2)     99 (19.3)         113 (20.5)    141 (19.7)
  ≥29 \[*n* (%)\]                                                         136 (34.8)    136 (26.6)        155 (28.1)    199 (27.8)
  **AGE AT MENARCHE, year**                                                                                             
  \<12 \[*n* (%)\]                                                        63 (19.0)     77 (15.3)         139 (24.7)    132 (18.1)
  12 \[*n* (%)\]                                                          84 (25.3)     111 (22.0)        160 (28.4)    210 (28.8)
  13 \[*n* (%)\]                                                          93 (28.0)     149 (29.5)        139 (24.7)    206 (28.3)
  ≥14 \[*n* (%)\]                                                         92 (27.7)     168 (33.3)        126 (22.3)    181 (24.8)
  **ORAL CONTRACEPTIVE USE, months**                                                                                    
  Never \[*n* (%)\]                                                       182 (47.5)    200 (39.8)        194 (40.3)    207 (31.1)
  1--48 \[*n* (%)\]                                                       101 (26.4)    107 (21.3)        142 (29.5)    181 (27.2)
  ≥48 \[*n* (%)\]                                                         100 (26.1)    196 (39.0)        145 (30.2)    278 (41.7)
  **POSTMENOPAUSAL STATUS**                                                                                             
  Yes \[*n* (%)\]                                                         290 (74.7)    393 (76.0)        251 (46.9)    502 (69.8)
  **POSTMENOPAUSAL HORMONE USE, months**                                                                                
  Never \[*n* (%)\]                                                       241 (61.6)    287 (58.5)        211 (39.2)    407 (58.4)
  1--60 \[*n* (%)\]                                                       71 (18.2)     91 (18.5)         166 (30.9)    147 (21.1)
  ≥60 \[*n* (%)\]                                                         79 (20.2)     113 (23.0)        161 (29.9)    143 (20.5)
  **PARITY, *n*/age at first birth, year**                                                                              
  Nulliparous \[*n* (%)\]                                                 69 (17.4)     77 (15.0)         113 (19.9)    94 (12.9)
  1--2/≤20 \[*n* (%)\]                                                    29 (7.3)      26 (5.1)          80 (14.1)     92 (12.6)
  1--2/≥20 \[*n* (%)\]                                                    115 (29.0)    155 (30.1)        208 (36.7)    314 (43.0)
  ≥3/≤20 \[*n* (%)\]                                                      77 (19.4)     74 (14.4)         80 (14.1)     92 (12.6)
  ≥3/≥20 \[*n* (%)\]                                                      106 (26.8)    183 (35.5)        86 (15.2)     138 (18.9)
  **FAMILY HISTORY OF OVARIAN CANCER[^a^](#tfn1){ref-type="table-fn"}**                                                 
  Yes \[*n* (%)\]                                                         50 (12.6)     42 (8.1)          56 (9.9)      46 (6.3)
  **SMOKING, pack-years**                                                                                               
  None \[*n* (%)\]                                                        242 (63.7)    333 (68.5)        303 (55.7)    376 (53.5)
  ≤20 \[*n* (%)\]                                                         75 (19.7)     100 (20.6)        137 (25.2)    187 (26.6)
  \>20 \[*n* (%)\]                                                        63 (16.6)     53 (10.9)         104 (19.1)    140 (19.9)
  **EDUCATION**                                                                                                         
  No diploma \[*n* (%)\]                                                  22 (5.8)      21 (4.1)          49 (8.6)      66 (9.0)
  High School diploma \[*n* (%)\]                                         136 (35.9)    133 (25.7)        179 (31.6)    192 (26.3)
  Post-high school education \[*n* (%)\]                                  221 (58.3)    364 (70.3)        339 (59.8)    472 (64.7)
  **MULTIVITAMIN USE[^b^](#tfn2){ref-type="table-fn"}**                                                                 
  Yes \[*n* (%)\]                                                         119 (44.9)    259 (52.4)        210 (38.1)    260 (36.4)
  **TUMOR HISTOLOGY, CASES**                                                                                            
  Serous \[*n* (%)\]                                                      255 (63.9)                      329 (58.1)    
  Mucinous \[*n* (%)\]                                                    11 (2.8)                        26 (4.6)      
  Endometrioid \[*n* (%)\]                                                77 (19.3)                       85 (15.0)     
  Clear cell \[*n* (%)\]                                                  25 (6.3)                        60 (10.6)     
  Other \[*n* (%)\]                                                       31 (7.8)                        66 (11.7)     

*Counts do not total to 2,233 subjects due to missing data for some variables*.

*^a^In first- or second-degree relative*.

*^b^At least four pills per week during the previous year for at least 48 months' duration of lifetime use (Mayo Clinic subjects) or at least three pills per week for at least 48 months during the past 60 months (Duke University subjects)*.

###### 

**Odds ratios (OR) and 95% CIs for the association between variants in *ATIC*, *SHMT2*, and *SLC46A1*and ovarian carcinoma stratified by multivitamin supplement use among 1,575 Caucasian subjects (Phase 1), Mayo Clinic, and Duke University**.

  Gene/SNP rsID                                Multivitamin non-users   Multivitamin users[^a^](#tfn3){ref-type="table-fn"}   *P*~int~[^c^](#tfn5){ref-type="table-fn"}   FDR[^d^](#tfn6){ref-type="table-fn"}                                                      
  -------------------------------------------- ------------------------ ----------------------------------------------------- ------------------------------------------- -------------------------------------- --------- -------- ------- ---------------- ------ ------
  ***ATIC***                                                                                                                                                                                                                                                        
  rs3772078                                    212/319                  95/160                                                6/14                                        0.9 (0.7--1.2)                         122/241   58/110   7/16    1.0 (0.7--1.4)   0.54   0.63
  rs2372536                                    137/225                  156/226                                               28/55                                       1.0 (0.8--1.2)                         98/167    64/162   25/44   0.9 (0.7--1.2)   0.52   0.63
  rs1880586                                    76/131                   176/268                                               71/108                                      1.1 (0.9--1.3)                         52/107    84/188   51/83   1.1 (0.9--1.4)   0.79   0.79
  rs1983462                                    147/235                  146/221                                               31/51                                       1.0 (0.8--1.3)                         97/166    73/180   18/32   0.8 (0.6--1.1)   0.27   0.45
  rs16853826                                   258/378                  65/122                                                1/7                                         0.7 (0.5--1.0)                         139/291   46/80    3/7     1.2 (0.8--1.7)   0.09   0.23
  rs7586969                                    115/199                  161/235                                               47/72                                       1.1 (0.9--1.4)                         81/135    83/185   24/58   0.8 (0.6--1.0)   0.07   0.23
  rs16853834                                   227/356                  85/140                                                12/11                                       1.0 (0.8--1.4)                         119/281   60/87    9/10    1.5 (1.1--2.1)   0.07   0.23
  rs1404772                                    279/450                  43/55                                                 2/2                                         1.3 (0.9--1.9)                         167/325   20/51    1/2     0.8 (0.5--1.3)   0.17   0.31
  rs7604984                                    106/189                  172/241                                               46/77                                       1.1 (0.9--1.3)                         81/128    77/187   30/62   0.8 (0.6--1.1)   0.12   0.26
  ***SHMT2***                                                                                                                                                                                                                                                       
  rs7301155[^e^](#tfn7){ref-type="table-fn"}   46/76                    48/101                                                16/25                                       1.0 (0.7--1.4)                         23/104    42/93    8/20    1.7 (1.1--2.6)   0.08   0.23
  rs2229716                                    300/462                  23/44                                                 1/1                                         0.8 (0.5--1.4)                         174/348   14/29    0/0     0.9 (0.5--1.9)   0.70   0.75
  ***SLC46A1***                                                                                                                                                                                                                                                     
  rs9894260                                    265/419                  57/86                                                 1/2                                         1.0 (0.7--1.4)                         151/319   32/58    4/1     1.5 (1.0--2.3)   0.08   0.23
  rs739439                                     216/350                  93/148                                                14/9                                        1.2 (0.9--1.5)                         126/237   56/124   5/17    0.8 (0.6--1.1)   0.09   0.23
  rs2239908                                    98/159                   163/253                                               62/94                                       1.0 (0.8--1.3)                         57/102    96/203   34/72   0.9 (0.7--1.2)   0.54   0.63
  rs17719944                                   270/426                  50/75                                                 4/6                                         1.0 (0.7--1.5)                         152/298   34/77    1/3     0.9 (0.6--1.3)   0.46   0.63

*^a^At least 4 pills per week during the previous year for at least 48 months' duration of lifetime use (Mayo Clinic subjects) or at least three pills per week for at least 48 months during the past 60 months (Duke University subjects)*.

*^b^Adjusted for age (\<40, 40--49, 50--59, 60--69, and 70+ years), region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina), body mass index, age at menarche, oral contraceptive use, postmenopausal status, postmenopausal hormone use, parity/age at first birth, smoking, and education (see Table [1](#T1){ref-type="table"} for categories). SNP effect was determined using a log-additive logistic regression model*.

*^c^*P* for interaction*.

*^d^False discovery rate *q*-value*.

*^e^Mayo Clinic subjects only*.

###### 

**Odds ratios (OR) and 95% CIs for the association between variants in *ATIC*, *SHMT2*, and *SLC46A1*and ovarian carcinoma stratified by multivitamin supplement use among 2,233 subjects (Phases 1 and 2), Mayo Clinic and Duke University**.

  Gene/SNP rsID                                  Multivitamin non-users   Multivitamin users[^a^](#tfn8){ref-type="table-fn"}   *P*~int~[^c^](#tfn10){ref-type="table-fn"}                                                                  
  ---------------------------------------------- ------------------------ ----------------------------------------------------- -------------------------------------------- ---------------- --------- --------- -------- ---------------- ------
  ***ATIC***                                                                                                                                                                                                                                
  rs3772078                                      323/438                  141/217                                               12/20                                        0.9 (0.7--1.1)   214/337   102/149   12/22    1.0 (0.7--1.3)   0.51
  rs2372536[^d^](#tfn11){ref-type="table-fn"}    224/323                  213/289                                               47/76                                        1.0 (0.8--1.2)   159/232   122/222   47/60    1.0 (0.8--1.3)   0.87
  rs1880586[^d^](#tfn11){ref-type="table-fn"}    125/191                  253/342                                               108/156                                      1.0 (0.9--1.2)   83/146    149/249   96/124   1.2 (0.9--1.4)   0.47
  rs1983462[^d^](#tfn11){ref-type="table-fn"}    208/315                  222/298                                               57/76                                        1.1 (0.9--1.3)   174/230   125/237   30/52    0.8 (0.6--1.0)   0.05
  rs16853826[^d^](#tfn11){ref-type="table-fn"}   384/516                  98/164                                                5/9                                          0.8 (0.6--1.0)   245/400   80/111    4/8      1.1 (0.8--1.6)   0.11
  rs7586969[^d^](#tfn11){ref-type="table-fn"}    166/261                  239/323                                               81/104                                       1.1 (0.9--1.3)   142/185   149/252   38/82    0.7 (0.6--0.9)   0.01
  rs16853834                                     349/483                  121/186                                               16/18                                        1.0 (0.8--1.3)   214/384   102/121   13/14    1.5 (1.1--2.0)   0.03
  rs1404772                                      425/609                  59/77                                                 3/3                                          1.2 (0.8--1.7)   290/447   38/70     1/2      0.7 (0.5--1.2)   0.20
  rs7604984                                      179/275                  239/306                                               69/108                                       1.0 (0.9--1.3)   130/184   142/248   57/85    0.9 (0.7--1.2)   0.35
  ***SHMT2***                                                                                                                                                                                                                               
  rs7301155[^d^](#tfn11){ref-type="table-fn"}    204/283                  187/296                                               42/66                                        0.9 (0.7--1.1)   133/239   147/211   28/42    1.3 (1.0--1.6)   0.08
  rs2229716[^d^](#tfn11){ref-type="table-fn"}    458/638                  28/49                                                 1/2                                          0.8 (0.5--1.3)   309/488   20/30     0/0      1.0 (0.5--2.0)   0.51
  ***SLC46A1***                                                                                                                                                                                                                             
  rs9894260[^d^](#tfn11){ref-type="table-fn"}    405/575                  78/111                                                3/3                                          1.0 (0.7--1.3)   272/433   50/83     6/3      1.1 (0.7--1.6)   0.62
  rs739439                                       323/475                  143/201                                               20/13                                        1.1 (0.9--1.4)   206/336   109/160   13/23    1.0 (0.7--1.3)   0.46
  rs2239908                                      139/213                  249/348                                               98/127                                       1.1 (0.9--1.3)   82/144    178/268   68/106   1.0 (0.8--1.2)   0.64
  rs17719944                                     404/576                  78/104                                                5/9                                          1.0 (0.7--1.3)   261/421   65/94     1/4      1.1 (0.7--1.6)   0.66

*^a^At least four pills per week during the previous year for at least 48 months' duration of lifetime use (Mayo Clinic subjects) or at least three pills per week for at least 48 months during the past 60 months (Duke University subjects)*.

*^b^Adjusted for age (\<40, 40--49, 50--59, 60--69, and 70+ years), region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina), body mass index, age at menarche, oral contraceptive use, postmenopausal status, postmenopausal hormone use, parity/age at first birth, smoking, and education (see Table [1](#T1){ref-type="table"} for categories). SNP effect was determined using a log-additive logistic regression model*.

*^c^*P* for interaction*.

*^d^SNP imputed from GWAS for all Duke University subjects (Phase 1 and Phase 2)*.

We performed the same analyses using Phase 2 samples as an independent replication, and then combined the Phase 1 and Phase 2 samples to increase statistical power. To account for the potential correlations among SNPs within genes, we performed both a multi-variant analysis and haplotype analysis. The multi-variant analysis was performed by calculating a likelihood ratio test (LRT) statistic comparing a regression model consisting of the main effects of those SNPs exhibiting significant interactions with multivitamin supplement use, their corresponding interaction terms, and potential confounding variables to a model without the SNP-by-multivitamin interaction terms. SNP main effects and their interaction terms were regressed under the ordinal (log-additive) genetic model. Permutation-based tests were then used to compute *P* values from a null distribution of the LRT statistic generated by permuting case status 10,000 times. The corresponding *P* value threshold was calculated as the probability of observing a permuted LRT statistic as extreme or more extreme than the observed LRT statistic. We also estimated haplotype frequencies for each gene, stratified and unstratified by regular multivitamin supplement use, by computing the posterior probabilities of all possible haplotypes for an individual, conditioned on the observed genotypes, using an expectation--maximization algorithm (Schaid et al., [@B31]). We used these probabilities to define haplotype design variables that estimated the number of each of the haplotypes carried by an individual, and retained only those with estimated frequencies of \>1%. We first tested whether differences among the haplotypes within each gene were associated statistically with ovarian carcinoma overall (*P* \< 0.016, Bonferroni-corrected for three genes). Next, associations between individual haplotypes and risk were estimated under ordinal genetic models (e.g., carriage of 0, 1, or 2 copies of a particular haplotype; Schaid, [@B30]). Individual associations were not considered statistically significant in the absence of global significance.

Statistical tests were two-sided, and were implemented with SAS (SAS Institute, NC), R (R Development Core Team, [@B28]), and Haplo.stats (Schaid, [@B30]) software.

Results
=======

There was no evidence of deviation from HWE in controls from both studies for any of the SNPs. The MAFs among controls ranged from 0.04 to 0.48 and were similar across study sites in Phase 1 (Table [A1](#TA1){ref-type="table"} in Appendix), Phase 2 (data not shown), and Phases 1 and 2 combined, with imputed SNPs in Phases 1 and 2 combined showing similar MAFs as typed SNPs in Phase 1 (Table [A1](#TA1){ref-type="table"} in Appendix). The distribution of some covariates varied among cases and controls at both Mayo Clinic and Duke University in Phase 1 (Table [A2](#TA2){ref-type="table"} in Appendix), Phase 2 (data not shown), and Phases 1 and 2 combined (Table [1](#T1){ref-type="table"}); however, histological subtypes of tumors were distributed comparably for both studies.

In Phase 1, the associations between six SNPs and ovarian carcinoma risk were modified by regular multivitamin supplement use at the smallest FDR *q*-value of 0.23: *ATIC* rs16853826, rs7586969 and rs16853834, *SHMT2* rs7301155, and *SLC46A1* rs9894260 and rs739439 (Table [2](#T2){ref-type="table"}). In stratified analyses, among women who took multivitamins regularly, the strongest associations were observed between ovarian carcinoma and *ATIC* rs16853834 (OR = 1.5, 95% CI = 1.1--2.1, *P* = 0.01) and *SHMT2* rs7301155 (OR = 1.7, 95% CI = 1.1--2.6, *P* = 0.01). Among non-regular supplement users, a trend was observed between ovarian carcinoma and *ATIC* rs16853826 (OR = 0.7, 95% CI = 0.5--1.0, *P* = 0.06). Comparable stratified analyses are shown in Table [A3](#TA3){ref-type="table"} in Appendix for Phase 2 samples, with none of the aforementioned SNPs showing statistically significant interactions in this smaller sample, although the direction of association among multivitamin supplement users was consistent for *ATIC* rs16853834 (OR = 1.6, 95% CI = 0.7--3.7). Combining Phase 1 and Phase 2 samples (968 cases and 1,265 controls; Table [3](#T3){ref-type="table"}), statistically significant interactions were observed between regular multivitamin supplement use and *ATIC* rs7586969 (OR = 0.7, 95% CI = 0.6--0.9) and *ATIC* rs16853834 (OR = 1.5, 95% CI = 1.1--2.0).

A multi-variant analysis was performed by calculating a LRT statistic comparing adjusted models that included *ATIC* rs7586969 and *ATIC* rs16853834, multivitamin use and the SNP-by-multivitamin interaction terms to a model without *ATIC* SNP-by-multivitamin interaction terms, and comparing this to a null distribution of the LRT statistic generated by permuting case status 10,000 times. The observed *P* value for *ATIC* (χ^2^ = 12.98, 2 df, *P* = 0.001) was more extreme than the *P* value derived from permutation testing (*P* = 0.009), suggesting the evidence is inconsistent with the null hypothesis of no association between *ATIC* SNP-by-multivitamin interactions and risk of ovarian carcinoma.

In haplotype analyses, only the *ATIC* gene was statistically significantly associated with ovarian carcinoma among regular multivitamin supplement users (Table [4](#T4){ref-type="table"}: global haplotype test *P* = 0.01; data not shown for *SHMT2* and *SLC46A1*). The two *ATIC* SNPs, rs7586969, and rs16853834, whose minor alleles showed opposing risks, did not share the same haplotype; however, the haplotypes they comprised mirrored their SNP risk associations among regular multivitamin supplement users. Haplotype \#1 accounted for 24% of all estimated haplotypes, comprised the minor allele of *ATIC* rs7586969 and was associated with a 24% decreased risk. Haplotype \#9 accounted for 13% of all estimated haplotypes, comprised the minor allele of *ATIC* rs16853834 and was associated with a 39% increased risk. A third haplotype, haplotype \#10, with 8% frequency, comprised common alleles for *ATIC* rs7586969 and rs16853834 and was associated with a 42% increased risk. Among non-users, haplotype \#5 was associated with a 27% decreased risk, but the global haplotype test was not statistically significant. None of the associations were statistically significant in the unstratified data. Squared correlations among the SNPs are shown in Figure [A1](#FA1){ref-type="fig"} in Appendix.

###### 

**Association[^a^](#tfn12){ref-type="table-fn"} between haplotypes derived from *ATIC* variants and ovarian carcinoma with and without stratification by multivitamin supplement use among 2,233 subjects (Phases 1 and 2), Mayo Clinic, and Duke University**.

  Haplotype[^b^](#tfn13){ref-type="table-fn"}   Multivitamin non-users   Multivitamin users   All subjects                                                        
  --------------------------------------------- ------------------------ -------------------- ------------------- ------ ------ ------------------- ------ ------ -------------------
                                                0.56                                                              0.01                              0.70          
  00110**10**00                                                          0.26                 1.04 (0.86--1.26)          0.24   0.76 (0.59--0.97)          0.25   0.93 (0.81--1.07)
  01000**00**01                                                          0.26                 0.98 (0.81--1.19)          0.25   0.82 (0.65--1.04)          0.26   0.94 (0.82--1.08)
  10000**10**11                                                          0.05                 1.23 (0.84--1.79)          0.05   0.74 (0.46--1.19)          0.05   1.05 (0.80--1.38)
  00010**10**00                                                          0.07                 1.16 (0.89--1.51)          0.07   0.96 (0.68--1.35)          0.06   1.01 (0.82--1.23)
  10001**00**00                                                          0.10                 0.73 (0.55--0.98)          0.10   1.10 (0.78--1.55)          0.10   0.95 (0.78--1.16)
  10100**10**11                                                          0.01                 0.69 (0.29--1.66)          0.02   1.28 (0.53--3.05)          0.01   0.77 (0.42--1.40)
  10101**00**00                                                          0.02                 1.13 (0.63--2.03)          0.03   1.50 (0.79--2.87)          0.02   1.17 (0.78--1.75)
  00000**01**00                                                          0.03                 0.87 (0.56--1.38)          0.03   1.52 (0.90--2.56)          0.03   1.02 (0.73--1.43)
  00100**01**00                                                          0.13                 1.00 (0.78--1.29)          0.13   1.39 (1.04--1.87)          0.13   1.16 (0.97--1.38)
  01100**00**01                                                          0.06                 1.07 (0.79--1.45)          0.08   1.42 (1.04--1.95)          0.06   1.12 (0.91--1.39)

*^a^Adjusted for age (\<40, 40--49, 50--59, 60--69, and 70+ yrs), residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina), body mass index, age at menarche, oral contraceptive use, postmenopausal status, postmenopausal hormone use, parity/age at first birth, smoking, and education (see Table [1](#T1){ref-type="table"} for categories). Haplotype associations were estimated using log-additive logistic regression models*.

*^b^Estimated using both cases and controls; SNPs that formed *ATIC* haplotypes were, in positional order, rs3772078, rs2372536, rs1880586, rs1983462, rs16853826, **rs7586969**, **rs16853834**, rs1404772, rs7604984, where 0 = common allele and 1 = rare allele. Bold indicates the two significant SNPs with opposing effects from Table [3](#T3){ref-type="table"}*.

For remaining SNPs with FDR *q*-values \> 0.23 in Phase 1, we estimated main effect associations with ovarian carcinoma (Table [A4](#TA4){ref-type="table"} in Appendix). An increased risk was observed among 12 carriers homozygous for the rare variant *SLC46A1* rs9894260 compared to carriers homozygous for the wildtype allele (OR = 5.4, 95% CI = 1.4--20.5). Similar results were seen using Phase 2 samples (data not shown), as well as Phase 1 and Phase 2 samples combined (Table [A5](#TA5){ref-type="table"} in Appendix). The main effect association between regular multivitamin supplement use and ovarian carcinoma in Phase 1 and Phase 2 samples combined was not statistically significant at *P* \< 0.05 (multivariable OR = 0.86, 95% CI = 0.70--1.06, *P* = 0.15; data not shown).

Discussion
==========

We evaluated the association between 15 SNPs in *ATIC*, *SHMT2*, and *SLC46A1* in the 1-C transfer pathway and ovarian carcinoma risk, and the modification of risk by regular multivitamin supplement use among 968 cases and 1,265 controls. There was little statistical evidence that SNPs or haplotypes in these genes were independently associated with ovarian carcinoma risk. However, the associations of *ATIC* rs7586969 and *ATIC* rs16853834 with ovarian carcinoma, when stratified by regular multivitamin supplement use and evaluated further in multi-variant and haplotype analyses, suggest the potentially important role that lifestyle factors may have in modifying genetic susceptibility.

We calculated that six interactions between SNPs and regular multivitamin use had an FDR *q*-value of 0.23 indicating that, out of 100 SNPs with this FDR *q*-value, 23 will be falsely positive, or approximately one in four. Further analyses in a larger sample showed consistent associations for two of these SNPs at *P* \< 0.05. *ATIC* rs7586969 and *ATIC* rs16853834 have MAF in our data of 0.39 and 0.16, respectively, but are weakly correlated with each other (pairwise LD *r*^2^ = 0.12). The power to detect these associations was relatively high: with an average exposure in our control group of 43% for regular multivitamin supplement use, we achieved close to 80% power needed with 1,054 cases using a ratio of 1:1.3 case--control pairs (actual: 968 cases and 1,265 controls) to detect an OR of 0.7 (*ATIC* rs7586969) at alpha = 0.05, and we would require 1,161 case--control pairs to detect an OR of 1.5 (*ATIC* rs16853834) under the log-additive genetic model (Quanto version 1.2, CA, USA, <http://hydra.usc.edu/gxe>). The power to detect the haplotype associations, where the greatest frequency was 24% (haplotype \#1), was lower. The presence of two SNPs in the same gene with relatively independent (and opposing) effects was resolved with haplotype analysis: the two SNPs do not share the same haplotype. Both the haplotype analysis and the multi-variant, permutation-based test suggest the data are inconsistent with the null hypothesis of no association between *ATIC* SNP-by-multivitamin interactions and risk of ovarian carcinoma. The aforementioned *ATIC* SNPs are intronic and, unlike exons, little is known of their role in the regulation of the final functional protein. However, because we genotyped tagSNPs, which merely identify a region in the gene at which an association is found, additional genotyping of the region (finemapping) and association testing is required to determine the precise causal variant(s). *In vitro* cell culture studies, where the nutrient medium can be manipulated, could then begin to unravel the functional impact of SNP-by-nutrient interactions.

ATIC catalyzes the final two steps in *de novo* purine biosynthesis, which is the main source of purine nucleotides (Kondo et al., [@B18]; Wolan et al., [@B39]). The final atom of the purine ring is supplied by folate, producing 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). Not only can AICAR induce apoptosis under certain conditions (Hallstrom et al., [@B12]), but as the substrate for ATIC, it can be catabolized to the purine "parent" nucleotide, inosine monophosphate (IMP), that ultimately generates two of the four bases, adenine and guanine. The bases are incorporated into DNA and RNA and also function as important sources of energy that drive most biologic reactions (e.g., ATP, GTP, UTP, CTP; Rodwell, [@B29]). Conceivably, ATIC may link nutrient metabolism vis-à-vis the 1-C transfer pathway to enable autophagy, which is the cellular catabolic degradation response to starvation or stress whereby cellular proteins, organelles, and cytoplasm are engulfed, digested, and recycled to sustain cellular metabolism (Mathew et al., [@B24]). For example, amino acid starvation is a potent inducer of autophagy (Mizushima, [@B25]), and defects in autophagy have been linked to tumorigenesis (Mathew et al., [@B24]).

Most individuals do not meet their Dietary Reference Intakes (DRI) for certain nutrients from foods alone. For example, among non-supplement users, folate intake (on average, \<300 μg/day; Zhang et al., [@B41]; Feigelson et al., [@B8]; Kelemen et al., [@B15]; Ericson et al., [@B6]) is less than the DRI (400 μg/day). A typical multivitamin contains a minimum of 400 μg of folic acid, thereby increasing some individuals' intakes to \>600 μg/day (Zhang et al., [@B41]; Feigelson et al., [@B8]). Pharmacologic doses of vitamin intake are hypothesized to be both chemo-preventive and chemo-progressive, and the mechanism(s) for these alterations may be related to the presence of existing pre-cancerous lesions, where vitamins like folate are required for growth by proliferating cells including tumors (Kim, [@B16]), and/or genetic susceptibility. Perhaps the best known example where nutrients influence gene-product function is that of high folate levels physically stabilizing, and thereby rescuing, MTHFR enzyme function in the presence of the *MTHFR* C677T SNP (Frosst et al., [@B9]; Anonymous, [@B1]; Guenther et al., [@B11]). Individuals with this SNP who also have higher folate intakes have lower risks of CVD (Klerk et al., [@B17]) and cancers of the colon (Giovannucci, [@B10]; Sharp and Little, [@B33]) than those with the SNP who have lower folate intakes.

Candidate SNP studies and GWAS examining main effect associations between SNPs and cancer risk have revealed relatively few causal variants. Given that some environmental exposures are known to play a role in the development of cancer (World Cancer Research Fund/American Institute for Cancer Research, [@B40]), it is entirely possible that the genetic effects assumed present but not yet found may be hidden within specific subsets of individuals defined by their environmental exposures, as shown in the current study. The SNPs in this investigation would not have been identified had we only focused on main effects, supporting the need for more studies such as this one to fully discern the interplay between genes and environment on risk of cancer. Large international consortia with well-annotated exposure and phenotype information, such as the international Ovarian Cancer Association Consortium, are well-positioned to provide the large sample sizes needed to detect effect modification, especially for SNPs with low MAF.

The strengths of this analysis include the use of stringent quality control for genotyping that resulted in few excluded or failed samples, with remaining call rates over 99%, and the large sample to investigate our findings for the SNP-by-multivitamin interactions, especially for *ATIC* SNPs. Population structure is unlikely, since analyses were restricted to Caucasians and there was no statistical heterogeneity in SNP associations between study sites. There are also potential limitations. For most other SNPs, the power to detect gene--environment interactions was low. Although we applied the FDR method to estimate the number of falsely positive interactions, the application of FDR has been traditionally to high dimensionality data and may not be applicable to smaller datasets. Nevertheless, the consistent associations in the combined Phases 1 and 2 sample of two of the six SNPs with lower FDR values from Phase 1, in addition to the multi-variant and haplotype analyses of *ATIC* SNP-by-multivitamin interactions, suggests the associations may not be due to chance. Another potential limitation is that we did not have information on dietary intake to verify which nutrient(s) was related to the modifying effects of multivitamins. Although self-reported multivitamin supplement use adequately represents the higher nutrient status among consumers compared to non-consumers (Zhang et al., [@B41], [@B42]; Kelemen et al., [@B15]), the potential for misclassification of this exposure may still exist in our study. The reference period for multivitamin use differed by site resulting in a slightly different definition in the Mayo Clinic and the Duke University studies. Our results for the interaction *P* values were somewhat attenuated compared to analyses that disregarded the information on duration of use (data not shown). Ostensibly, misclassification of exposure, although present, did not appear to influence our findings substantially.

In summary, this report provides little statistical evidence that SNPs in *ATIC*, *SHMT2*, and *SLC46A1* are independently associated with ovarian carcinoma risk. The statistical interaction of *ATIC* SNPs with regular multivitamin intake and ATIC's role in cellular metabolism and autophagy may support these findings as relevant to ovarian health and disease processes.
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![**Linkage disequilibrium plot for tagSNPs in *AITC* using 2,233 Caucasian subjects, Mayo Clinic, and Duke University**. Numbers in squares indicate the correlation (*r*^2^) between SNPs.](fgene-03-00033-a001){#FA1}

###### 

**Descriptive information and test statistics for SNPs in *ATIC*, *SHMT2*, and *SLC46A1* among Caucasian controls, Mayo Clinic, and Duke University**.

  Gene        Chr   Chr Position (bp)[^a^](#tfn14){ref-type="table-fn"}   SNP rsID                                       Location                                 Phase 1   Phases 1 and 2                                                                  
  ----------- ----- ----------------------------------------------------- ---------------------------------------------- ---------------------------------------- --------- ---------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  *ATIC*      2     215898090                                             rs3772078                                      Intron                                   0.88      0.88             0.74   0.19   0.19   0.19   1.00   0.80   0.85   0.20   0.18   0.19
              2     215898265                                             rs2372536[^d^](#tfn17){ref-type="table-fn"}    Exon[^e^](#tfn18){ref-type="table-fn"}   0.23      0.54             0.71   0.32   0.34   0.33   0.32   0.40   0.18   0.32   0.33   0.32
              2     215903416                                             rs1880586[^d^](#tfn17){ref-type="table-fn"}    Intron                                   0.77      0.36             0.35   0.48   0.48   0.48   0.94   0.46   0.51   0.49   0.48   0.48
              2     215903526                                             rs1983462[^d^](#tfn17){ref-type="table-fn"}    Intron                                   0.58      0.30             0.23   0.32   0.32   0.32   0.77   0.61   0.90   0.32   0.33   0.33
              2     215913412                                             rs16853826[^d^](#tfn17){ref-type="table-fn"}   Intron                                   1.00      0.69             0.77   0.13   0.13   0.13   1.00   0.30   0.38   0.13   0.12   0.13
              2     215915470                                             rs7586969[^d^](#tfn17){ref-type="table-fn"}    Intron                                   0.42      0.38             0.94   0.39   0.37   0.38   0.47   0.53   1.00   0.39   0.39   0.39
              2     215918481                                             rs16853834                                     Intron                                   0.36      0.49             1.00   0.15   0.15   0.15   0.61   0.89   0.60   0.15   0.16   0.16
              2     215918544                                             rs1404772                                      Intron                                   1.00      0.65             0.78   0.07   0.06   0.06   1.00   0.73   1.00   0.07   0.06   0.06
              2     215925884                                             rs7604984                                      3′ Flanking                              0.84      0.70             0.94   0.40   0.40   0.40   0.53   0.24   0.19   0.39   0.39   0.39
  *SHMT2*     12    55909088                                              rs7301155[^d^](#tfn17){ref-type="table-fn"}    5′ Flanking                              0.67      --               0.67   0.34   --     0.34   0.70   0.39   0.39   0.34   0.30   0.32
              12    55912849                                              rs2229716[^d^](#tfn17){ref-type="table-fn"}    Exon[^f^](#tfn19){ref-type="table-fn"}   1.00      1.00             1.00   0.04   0.04   0.04   1.00   0.22   0.67   0.04   0.04   0.04
  *SLC46A1*   17    23743752                                              rs9894260[^d^](#tfn17){ref-type="table-fn"}    Intron                                   0.34      0.56             0.19   0.08   0.09   0.08   1.00   0.36   0.36   0.08   0.09   0.08
              17    23747949                                              rs739439                                       3′ UTR                                   0.72      0.16             0.44   0.17   0.20   0.18   0.66   0.38   0.71   0.18   0.19   0.18
              17    23749392                                              rs2239908                                      3′ UTR                                   0.24      0.65             0.23   0.44   0.46   0.45   0.67   0.50   0.40   0.45   0.45   0.45
              17    23753580                                              rs17719944                                     Intron                                   0.55      1.00             0.70   0.09   0.10   0.10   0.80   0.51   0.51   0.09   0.09   0.09

*^a^Base pairs on genome build 36; UTR, untranslated region*.

*^b^*P* values from the chi-square test assessing deviation of genotype frequencies among controls from those expected under Hardy--Weinberg Equilibrium*.

*^c^Minor allele frequency*.

*^d^Imputed SNPs in Phase 2 samples*.

*^e^Non-synonymous polymorphism*.

*^f^Synonymous polymorphism*.

###### 

**Characteristics of 1,575 Caucasian subjects (Phase 1), Mayo Clinic, and Duke University**.

                                                                           Mayo Clinic   Duke University                 
  ------------------------------------------------------------------------ ------------- ----------------- ------------- -------------
  Age, years \[mean (SD)\]                                                 60.8 (12.8)   60.0 (12.9)       56.8 (10.4)   54.6 (12.0)
  **BODY MASS INDEX, kg/m^2^**                                                                                           
  \<23 \[*n* (%)\]                                                         57 (18.5)     103 (23.7)        96 (29.0)     132 (28.1)
  23--26 \[*n* (%)\]                                                       77 (24.9)     125 (28.8)        85 (25.7)     117 (25.0)
  26--29 \[*n* (%)\]                                                       61 (19.7)     88 (20.3)         75 (22.7)     110 (23.5)
  ≥29 \[*n* (%)\]                                                          114 (36.9)    118 (27.2)        75 (22.7)     110 (23.5)
  **AGE AT MENARCHE, year**                                                                                              
  \<12 \[*n* (%)\]                                                         46 (18.5)     67 (15.7)         88 (25.7)     85 (17.7)
  12 \[*n* (%)\]                                                           60 (24.1)     97 (22.8)         99 (29.0)     142 (29.5)
  13 \[*n* (%)\]                                                           66 (26.5)     126 (29.6)        82 (24.0)     140 (29.1)
  ≥14 \[*n* (%)\]                                                          77 (30.9)     136 (31.9)        73 (21.4)     114 (23.7)
  **ORAL CONTRACEPTIVE USE, months**                                                                                     
  Never \[*n* (%)\]                                                        150 (49.7)    166 (38.9)        116 (34.5)    148 (31.0)
  1--48 \[*n* (%)\]                                                        75 (24.8)     90 (21.1)         105 (31.3)    133 (27.8)
  ≥48 \[*n* (%)\]                                                          77 (25.5)     171 (40.1)        115 (34.2)    197 (41.2)
  **POSTMENOPAUSAL STATUS**                                                                                              
  Yes \[*n* (%)\]                                                          222 (73.0)    328 (75.1)        251 (80.2)    312 (66.1)
  **POSTMENOPAUSAL HORMONE USE, months**                                                                                 
  Never \[*n* (%)\]                                                        193 (62.7)    244 (58.5)        108 (33.4)    270 (59.3)
  1--60 \[*n* (%)\]                                                        54 (17.5)     79 (18.9)         114 (35.3)    96 (21.1)
  ≥60 \[*n* (%)\]                                                          61 (19.8)     94 (22.5)         101 (31.3)    89 (19.6)
  **PARITY, *n*/age at first birth, year**                                                                               
  Nulliparous \[*n* (%)\]                                                  56 (18.0)     64 (14.7)         71 (20.7)     64 (13.3)
  1--2/≤20 \[*n* (%)\]                                                     20 (6.4)      24 (5.5)          46 (13.4)     57 (11.9)
  1--2/≥20 \[*n* (%)\]                                                     91 (29.2)     130 (29.9)        125 (36.4)    211 (43.9)
  ≥3/≤20 \[*n* (%)\]                                                       59 (18.9)     63 (14.5)         49 (14.3)     61 (12.7)
  ≥3/≥20 \[*n* (%)\]                                                       86 (27.6)     154 (35.4)        52 (15.2)     88 (18.3)
  **FAMILY HISTORY OF OVARIAN CANCER[^a^](#tfn20){ref-type="table-fn"}**                                                 
  Yes \[*n* (%)\]                                                          41 (13.1)     33 (7.5)          33 (9.6)      26 (5.4)
  **SMOKING, pack-years**                                                                                                
  None \[*n* (%)\]                                                         194 (65.3)    279 (68.2)        190 (57.8)    250 (54.1)
  ≤20 \[*n* (%)\]                                                          56 (18.9)     82 (20.1)         80 (24.3)     121 (26.2)
  \>20 \[*n* (%)\]                                                         47 (15.8)     48 (11.7)         59 (17.9)     91 (19.7)
  **EDUCATION**                                                                                                          
  No diploma \[*n* (%)\]                                                   18 (6.1)      19 (4.3)          26 (7.6)      42 (8.7)
  High School diploma \[*n* (%)\]                                          107 (36.2)    116 (26.5)        105 (30.6)    131 (27.2)
  Post-high school education \[*n* (%)\]                                   171 (57.8)    303 (69.2)        212 (61.8)    308 (64.0)
  **MULTIVITAMIN USE[^b^](#tfn21){ref-type="table-fn"}**                                                                 
  Yes \[*n* (%)\]                                                          73 (39.9)     217 (51.7)        115 (35.0)    161 (34.6)
  **TUMOR HISTOLOGY, CASES**                                                                                             
  Serous \[*n* (%)\]                                                       191 (61.2)                      206 (60.2)    
  Mucinous \[*n* (%)\]                                                     8 (2.6)                         19 (5.7)      
  Endometrioid \[*n* (%)\]                                                 63 (20.2)                       53 (15.5)     
  Clear cell \[*n* (%)\]                                                   20 (6.4)                        28 (8.2)      
  Other \[*n* (%)\]                                                        30 (9.6)                        36 (10.5)     

*Counts do not total to 1,575 subjects due to missing data for some variables*.

*^a^In first- or second-degree relative*.

*^b^At least four pills per week during the previous year for at least 48 months' duration of lifetime use (Mayo Clinic subjects) or at least three pills per week for at least 48 months during the past 60 months (Duke University subjects)*.

###### 

**Odds ratios (OR) and 95% CIs for the association between variants in *ATIC*, *SHMT2*, and *SLC46A1*and ovarian carcinoma stratified by multivitamin supplement use among 658 subjects included in the GWAS (Phase 2), Mayo Clinic, and Duke University**.

  Gene/SNP rsID   Regular multivitamin users[^a^](#tfn22){ref-type="table-fn"}   Regular multivitamin non-users   *P*~int~[^c^](#tfn24){ref-type="table-fn"}                                                                    
  --------------- -------------------------------------------------------------- -------------------------------- -------------------------------------------- ------------------ ----------- ------- ------- ----------------- ------
  ***ATIC***                                                                                                                                                                                                                    
  rs3772078       92/96                                                          44/39                            5/6                                          0.9 (0.4--2.1)     111/119     46/57   6/6     0.9 (0.4--1.7)    0.92
  rs2372536       61/65                                                          58/60                            22/16                                        1.1 (0.6--2.1)     87/98       57/63   19/21   1.2 (0.7--2.1)    0.85
  rs1880586       31/39                                                          65/61                            45/41                                        0.9 (0.5--1.7)     49/60       77/74   37/48   1.1 (0.6--1.9)    0.90
  rs1983462       77/64                                                          52/57                            12/20                                        0.7 (0.4--1.4)     61/80       76/77   26/25   1.0 (0.6--1.8)    0.85
  rs16853826      106/109                                                        34/31                            1/1                                          0.9 (0.3--2.4)     126/138     33/42   4/2     0.8 (0.3--1.8)    0.77
  rs7586969       61/50                                                          66/67                            14/24                                        0.7 (0.4--1.4)     51/62       78/88   34/32   1.0 (0.5--1.7)    0.82
  rs16853834      95/103                                                         42/34                            4/4                                          1.6 (0.7--3.7)     122/127     36/46   4/7     1.0 (0.4--2.1)    0.73
  rs1404772       123/122                                                        18/19                            0/0                                          0.6 (0.1--2.8)     146/159     16/22   1/1     0.8 (0.2--2.6)    0.99
  rs7604984       49/56                                                          65/61                            27/23                                        1.1 (0.6--2.2)     73/86       67/65   23/31   1.2 (0.7--2.1)    0.60
  ***SHMT2***                                                                                                                                                                                                                   
  rs7301155       65/69                                                          63/60                            13/12                                        0.6 (0.3--1.3)     85/80       64/82   14/20   0.6 (0.3--1.1)    0.43
  rs2229716       135/140                                                        6/1                              0/0                                          5.8 (0.3--111.9)   185/176     5/5     0/1     1.6 (0.2--13.2)   0.68
  ***SLC46A1***                                                                                                                                                                                                                 
  rs9894260       121/114                                                        18/25                            2/2                                          0.7 (0.2--1.9)     140/156     21/25   2/1     0.6 (0.2--1.8)    0.56
  rs739439        80/99                                                          53/36                            8/6                                          1.0 (0.4--2.2)     107/125     50/53   6/4     1.0 (0.5--2.1)    0.39
  rs2239908       25/42                                                          82/65                            34/34                                        0.9 (0.5--1.8)     41/54       86/95   36/33   1.6 (0.9--2.8)    0.03
  rs17719944      109/123                                                        31/17                            0/1                                          4.0 (1.1--14.8)    1,340/150   28/29   1/3     0.5 (0.2--1.4)    0.02

*^a^At least four pills per week during the previous year for at least 48 months' duration of lifetime use (Mayo Clinic subjects) or at least three pills per week for at least 48 months during the past 60 months (Duke University subjects)*.

*^b^Adjusted for age (\<40, 40--49, 50--59, 60--69, and 70+ years), region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina), body mass index, age at menarche, oral contraceptive use, postmenopausal status, postmenopausal hormone use, parity/age at first birth, smoking, and education. SNP effect was determined using a log-additive logistic regression model*.

*^c^*P* for interaction*.

###### 

**Odds ratios (OR) and 95% CIs for the main effect association between variants in *ATIC*, *SHMT2*, and *SLC46A1* and ovarian carcinoma among 1,575 Caucasian subjects (Phase 1), Mayo Clinic, and Duke University**.

  Gene/SNP rsID   Homozygous major allele (referent)   Heterozygous   Homozygous minor allele   *P* value (2 df)   Ordinal (per minor allele)                                                         
  --------------- ------------------------------------ -------------- ------------------------- ------------------ ---------------------------- ----- ----- ----------------- ------ ---------------- ------
  ***ATIC***                                                                                                                                                                                          
  rs3772078       415                                  583            201                       279                1.0 (0.8--1.3)               20    30    0.9 (0.5--1.7)    0.98   1.0 (0.8--1.2)   0.93
  rs2372536       304                                  409            279                       399                1.0 (0.8--1.2)               67    103   0.9 (0.6--1.3)    0.76   0.9 (0.8--1.1)   0.46
  rs1880586       167                                  245            336                       473                1.0 (0.8--1.3)               149   201   1.1 (0.8--1.4)    0.88   1.0 (0.9--1.2)   0.61
  rs1983462       319                                  417            275                       417                0.9 (0.7--1.1)               60    86    0.9 (0.6--1.3)    0.42   0.9 (0.8--1.1)   0.30
  rs16853826      497                                  696            150                       210                1.0 (0.8--1.3)               8     14    0.8 (0.3--2.0)    0.93   1.0 (0.8--1.2)   0.84
  rs7586969       259                                  348            301                       436                0.9 (0.7--1.1)               93    134   0.9 (0.7--1.3)    0.76   1.0 (0.8--1.1)   0.55
  rs16853834      442                                  657            187                       241                1.1 (0.9--1.4)               26    22    1.7 (0.9--3.1)    0.13   1.2 (1.0--1.4)   0.06
  rs1404772       568                                  807            84                        108                1.1 (0.8--1.5)               3     4     1.1 (0.2--5.0)    0.86   1.1 (0.8--1.4)   0.59
  rs7604984       242                                  332            317                       442                1.0 (0.8--1.2)               96    144   0.9 (0.7--1.2)    0.84   1.0 (0.8--1.1)   0.64
  ***SHMT2***                                                                                                                                                                                         
  rs7301155       121                                  187            153                       202                1.2 (0.9--1.6)               37    49    1.2 (0.7--1.9)    0.56   1.1 (0.9--1.4)   0.33
  rs2229716       601                                  838            51                        79                 0.9 (0.6--1.3)               2     1     2.4 (0.2--27.0)   0.63   0.9 (0.7--1.3)   0.70
  ***SLC46A1***                                                                                                                                                                                       
  rs9894260       531                                  768            111                       148                1.1 (0.8--1.4)               9     3     5.4 (1.4--20.5)   0.04   1.2 (0.9--1.5)   0.14
  rs739439        435                                  610            191                       283                0.9 (0.8--1.2)               26    27    1.3 (0.8--2.3)    0.48   1.0 (0.8--1.2)   0.87
  rs2239908       197                                  270            324                       473                0.9 (0.7--1.2)               131   175   1.0 (0.8--1.4)    0.76   1.0 (0.9--1.2)   0.99
  rs17719944      534                                  753            113                       157                1.0 (0.8--1.3)               7     9     1.1 (0.4--3.1)    0.96   1.0 (0.8--1.3)   0.81

*^a^Adjusted for age (\<40, 40--49, 50--59, 60--69, and 70+ years) and region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina)*.

###### 

**Odds ratios (OR) and 95% CIs for the main effect association between variants in *ATIC*, *SHMT2*, and *SLC46A1* and ovarian carcinoma among 2,233 Caucasian subjects (Phases 1 and 2), Mayo Clinic, and Duke University**.

  Gene/SNP rsID   Homozygous major allele (referent)   Heterozygous   Homozygous minor allele   *P* value (2 df)   Ordinal (per minor allele)                                                        
  --------------- ------------------------------------ -------------- ------------------------- ------------------ ---------------------------- ----- ----- ---------------- ------ ---------------- ------
  ***ATIC***                                                                                                                                                                                         
  rs3772078       623                                  810            294                       384                1.0 (0.8--1.2)               32    43    1.0 (0.6--1.6)   0.98   1.0 (0.8--1.2)   0.85
  rs2372536       455                                  583            399                       530                1.0 (0.8--1.2)               109   143   1.0 (0.7--1.3)   0.95   1.0 (0.9--1.1)   0.84
  rs1880586       248                                  348            482                       619                1.1 (0.9--1.3)               235   297   1.1 (0.9--1.4)   0.69   1.0 (0.9--1.2)   0.48
  rs1983462       463                                  573            406                       559                0.9 (0.8--1.1)               98    133   0.9 (0.7--1.2)   0.54   0.9 (0.8--1.1)   0.32
  rs16853826      734                                  957            220                       291                1.0 (0.8--1.2)               14    17    1.1 (0.5--2.3)   0.92   1.0 (0.8--1.2)   0.97
  rs7586969       377                                  469            448                       602                0.9 (0.8--1.1)               141   192   0.9 (0.7--1.2)   0.66   0.9 (0.8--1.1)   0.39
  rs16853834      665                                  902            268                       328                1.1 (0.9--1.3)               34    33    1.4 (0.8--2.2)   0.32   1.1 (1.0--1.3)   0.15
  rs1404772       846                                  1,107          118                       152                1.0 (0.8--1.3)               4     5     1.1 (0.3--4.1)   0.99   1.0 (0.8--1.3)   0.98
  rs7604984       367                                  483            455                       577                1.0 (0.9--1.3)               146   202   1.0 (0.7--1.2)   0.75   1.0 (0.9--1.1)   0.87
  ***SHMT2***                                                                                                                                                                                        
  rs7301155       398                                  545            404                       530                1.0 (0.9--1.3)               86    114   1.0 (0.8--1.4)   0.87   1.0 (0.9--1.2)   0.64
  rs2229716       902                                  1,175          63                        86                 0.9 (0.7--1.3)               2     2     1.1 (0.1--7.7)   0.92   0.9 (0.7--3.3)   0.73
  ***SLC46A1***                                                                                                                                                                                      
  rs9894260       799                                  1,056          152                       202                1.0 (0.8--1.2)               13    6     3.1 (1.1--8.3)   0.08   1.1 (0.9--1.3)   0.44
  rs739439        627                                  845            298                       281                1.0 (0.9--1.3)               40    39    1.4 (0.9--2.2)   0.36   1.1 (0.9--1.3)   0.25
  rs2239908       267                                  370            495                       642                1.1 (0.9--1.3)               203   251   1.1 (0.9--1.4)   0.73   1.1 (0.9--1.2)   0.43
  rs17719944      784                                  1,040          174                       211                1.1 (0.9--1.4)               8     13    0.9 (0.4--2.1)   0.66   1.1 (0.9--1.3)   0.53

*^a^Adjusted for age (\<40, 40--49, 50--59, 60--69, and 70+ years) and region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina)*.
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